文献速递产科麻醉术前评估与围术期医学

住院产前患者皮下普通肝素不同剂量与活化部分凝血活酶时间:回顾性队列分析

Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis.
PubMed 文献 · Anesth Analg · 2022-01-01

该回顾性队列研究纳入2016至2019年芝加哥大学住院产前接受皮下普通肝素(UFH)血栓预防的患者321例,按孕周给予5000、7500或10000单位每12小时。33例(10.3%)出现aPTT>40秒,总日剂量15000或20000单位时aPTT升高可能性增加。

要点

  • 住院产前患者皮下UFH 5000单位每12小时时aPTT>40秒概率为2.8%。
  • 7500单位每12小时时aPTT>40秒概率为18.9%,10000单位每12小时为14.6%。
  • 总日剂量15000或20000单位皮下UFH时aPTT升高可能性大。

核心结论

  • 住院产前患者皮下UFH总日剂量15000或20000单位时,aPTT升高可能性大。

研究设计与样本

  • 回顾性队列研究,使用芝加哥大学药房数据库识别2016年6月1日至2019年7月1日住院产前接受皮下UFH的患者321例。

主要发现

  • 321例中33例(10.3%)aPTT>40秒,其中4例(12.1%)接受5000单位每12小时,14例(42.2%)接受7500单位每12小时,15例(45.5%)接受10000单位每12小时。
  • aPTT>40秒的可能性在5000单位每12小时组为2.8%,7500单位每12小时组为18.9%,10000单位每12小时组为14.6%。

关键数值与推荐

  • 机构方案:孕早期5000单位每12小时,孕中期7500单位每12小时,孕晚期10000单位每12小时皮下UFH。
  • aPTT在肝素第三剂后2小时获取,血小板计数在4天后获取。

临床怎么用

  • 住院产前患者接受皮下UFH血栓预防时,尤其总日剂量15000或20000单位,应关注aPTT升高风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is a leading cause of maternal morbidity and mortality in the United States. Subcutanous unfractionated heparin (UFH) has been used for decades for VTE prophylaxis and under many obstetric quality of care initiatives, hospitalized antepartum patients now receive doses as high as 10,000 units every 12 hours. This practice increases the likelihood of UFH administration around the time that epidural labor analgesia is requested or neuraxial analgesia for cesarean delivery is needed. To clarify the effect of UFH on coagulation, we reviewed the care of hospitalized antepartum patients receiving VTE prophylaxis with UFH to determine the incidence of concurrent abnormal activated partial thromboplastin time (aPTT) values and associated risk factors. METHODS: This retrospective cohort study used data from the University of Chicago Pharmacy database to identify hospitalized antepartum patients receiving subcutaneous UFH from June 1, 2016 to July 1, 2019. Our institutional protocol states that all patients hospitalized for antepartum conditions should receive pharmacologic prophylaxis empirically unless contraindicated. For patients receiving UFH, dosing was based on gestational age: 5000 units every 12 hours for first trimester antepartum patients, 7500 units every 12 hours for second trimester patients, and 10,000 units every 12 hours for patients in the third trimester. As per protocol, aPTT values were obtained 2 hours after the third dose of heparin, and platelet counts after 4 days. Data collection included demographics, comorbidities, heparin doses, aPTT values, platelet counts, creatinine if available, and anesthetic type and complications. Logistic regression was performed to determine the association between elevated aPTT >40 seconds and study variables. RESULTS: Of the 321 antepartum patients who received subcutaneous UFH, 33 (10.3%) had an aPTT >40 seconds, 4 of those 33 patients (12.1%) received 5000 units every 12 hours, 14 (42.2%) received 7500 units every 12 hours, and 15 (45.5%) received 10,000 units every 12 hours. The likelihood of a patient having aPTT >40 seconds was 2.8% with 5000 units every 12 hours, 18.9% with 7500 units every 12 hours, and 14.6% with 10,000 units every 12 hours. CONCLUSIONS: Elevated aPTT values are likely with total daily doses of 15,000 or 20,000 units subcutaneous UFH in hospitalized antepartum patients.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Elmofty DH, Tucker A, Wuenstel AM, et al. Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis. Anesth Analg. 2022. PMID: 35020621. doi:10.1213/ANE.0000000000005866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。